Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2025) 109 MTE5 | DOI: 10.1530/endoabs.109.MTE5

Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom


The management of thyroid eye disease has evolved significantly over the last 5-10 years. While methylprednisolone remains the mainstay of treatment for patients with active, moderate to severe disease, newer immunotherapies are changing how we manage this heterogeneous condition. Emerging therapeutic options add complexity to management decisions, but have the potential to hugely benefit our patients.

Volume 109

Society for Endocrinology BES 2025

Harrogate, UK
10 Mar 2025 - 12 Mar 2025

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches